美国食品和药物管理局批准了第一种乳腺癌药物Veppanu. FDA approves first-of-its-kind breast cancer drug Veppanu.

美国食品和药物管理局批准了Veppanu,这是首个针对已发病的激素受体阳性HER2阴性的乳腺癌成年人使用的新型药. The U.S. FDA has approved Veppanu, a first-of-its-kind drug for adults with advanced, hormone receptor-positive, HER2-negative breast cancer that has spread. 治疗使用一种新机制向特定蛋白质,针对之前经过激素疗法后疾病进展的患者. The treatment targets specific proteins using a novel mechanism and is for patients whose disease has progressed after prior hormone therapies. 美国食品和药物管理局还批准了一项伴侣血液检测, 以确定符合条件的患者. The FDA also approved a companion blood test to identify eligible patients.